443 related articles for article (PubMed ID: 23748522)
1. Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitors.
Freeman JS
Postgrad Med; 2013 May; 125(3):214-26. PubMed ID: 23748522
[TBL] [Abstract][Full Text] [Related]
2. SGLT2-inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2-inhibitors in clinical practice.
Cuypers J; Mathieu C; Benhalima K
Acta Clin Belg; 2013; 68(4):287-93. PubMed ID: 24455799
[TBL] [Abstract][Full Text] [Related]
3. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes.
Nauck MA
Drug Des Devel Ther; 2014; 8():1335-80. PubMed ID: 25246775
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus.
Chen LH; Leung PS
Diabetes Obes Metab; 2013 May; 15(5):392-402. PubMed ID: 23331516
[TBL] [Abstract][Full Text] [Related]
5. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
Kurosaki E; Ogasawara H
Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
[TBL] [Abstract][Full Text] [Related]
6. Sodium glucose co-transporter 2 (SGLT2) inhibition with canagliflozin in type 2 diabetes mellitus.
Said S; Hernandez GT
Cardiovasc Hematol Agents Med Chem; 2013 Sep; 11(3):203-6. PubMed ID: 24025022
[TBL] [Abstract][Full Text] [Related]
7. A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition.
Basile J
Postgrad Med; 2011 Jul; 123(4):38-45. PubMed ID: 21680987
[TBL] [Abstract][Full Text] [Related]
8. Canagliflozin: a review of its use in patients with type 2 diabetes mellitus.
Plosker GL
Drugs; 2014 May; 74(7):807-24. PubMed ID: 24831734
[TBL] [Abstract][Full Text] [Related]
9. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.
Neumiller JJ; White JR; Campbell RK
Drugs; 2010 Mar; 70(4):377-85. PubMed ID: 20205482
[TBL] [Abstract][Full Text] [Related]
10. Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes.
Nisly SA; Kolanczyk DM; Walton AM
Am J Health Syst Pharm; 2013 Feb; 70(4):311-9. PubMed ID: 23370138
[TBL] [Abstract][Full Text] [Related]
11. Sodium-glucose co-transporter 2 inhibition in diabetes treatment: current evidence and future perspectives.
Rizos EC; Elisaf MS
Curr Pharm Des; 2014; 20(22):3647-56. PubMed ID: 24040872
[TBL] [Abstract][Full Text] [Related]
12. A paradigm shift in diabetes therapy--dapagliflozin and other SGLT2 inhibitors.
Chao EC
Discov Med; 2011 Mar; 11(58):255-63. PubMed ID: 21447284
[TBL] [Abstract][Full Text] [Related]
13. Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.
Jabbour SA; Whaley JM; Tirmenstein M; Poucher SM; Reilly TP; Boulton DW; Saye J; List JF; Parikh S
Postgrad Med; 2012 Jul; 124(4):62-73. PubMed ID: 22913895
[TBL] [Abstract][Full Text] [Related]
14. Canagliflozin: a novel treatment option for type 2 diabetes.
Dietrich E; Powell J; Taylor JR
Drug Des Devel Ther; 2013; 7():1399-408. PubMed ID: 24285921
[TBL] [Abstract][Full Text] [Related]
15. Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations.
Scheen AJ
Expert Opin Drug Metab Toxicol; 2014 May; 10(5):647-63. PubMed ID: 24387329
[TBL] [Abstract][Full Text] [Related]
16. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors.
Oliva RV; Bakris GL
J Am Soc Hypertens; 2014 May; 8(5):330-9. PubMed ID: 24631482
[TBL] [Abstract][Full Text] [Related]
17. Sodium glucose co-transporter 2 inhibitors: a novel approach to the management of type 2 diabetes mellitus.
Davis CS; Fleming JW; Warrington LE
J Am Assoc Nurse Pract; 2014 Jul; 26(7):356-63. PubMed ID: 24895099
[TBL] [Abstract][Full Text] [Related]
18. Ramping glucosuria for management of type 2 diabetes mellitus: an emerging cynosure.
Malla P; Kumar R; Mahapatra MK; Kumar M
Med Res Rev; 2014 Nov; 34(6):1146-67. PubMed ID: 24633706
[TBL] [Abstract][Full Text] [Related]
19. Canagliflozin: a new hope in the antidiabetic armamentarium.
Katsi VK; Michalakeas CA; Grassos CE; Vamvakou GD; Lekakis JP; Tousoulis D; Stefanadis CI; Makris TK; Kallikazaros IE
Recent Pat Cardiovasc Drug Discov; 2013 Dec; 8(3):216-20. PubMed ID: 24359233
[TBL] [Abstract][Full Text] [Related]
20. SGLT2 inhibition with dapagliflozin -- a novel approach for the management of type 2 diabetes.
Kilov G; Leow S; Thomas M
Aust Fam Physician; 2013 Oct; 42(10):706-10. PubMed ID: 24130972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
